Company Overview

ZYUS Life Sciences Corporation is a Canadian life sciences and biotechnology company focused on the development and commercialization of cannabinoid-based pharmaceutical and nutraceutical products. The company operates primarily in the medical cannabis, bioscience, and drug development sectors, with an emphasis on creating standardized cannabinoid formulations intended for clinical and therapeutic use. Its activities have included cultivation, extraction, formulation development, clinical research, and intellectual property development tied to cannabinoid science.

The company’s primary revenue and development focus has centered on medical cannabis products, cannabinoid-derived compounds, and research collaborations involving human health applications. ZYUS has positioned itself around pharmaceutical-grade cannabinoid production and evidence-based product development, differentiating itself from recreational cannabis-focused operators. The company evolved from earlier cannabis-sector operations and reoriented toward life sciences and clinical development initiatives as the broader Canadian cannabis industry matured and became more competitive.

Business Operations

ZYUS conducts operations through cannabinoid research, product formulation, cultivation oversight, and pharmaceutical development initiatives. Its business model has historically included licensing, product commercialization, and research-driven partnerships tied to cannabinoid therapeutics. The company has pursued proprietary formulations and standardized dosage technologies designed for medical applications, with operations primarily concentrated in Canada. Publicly available information indicates that the company has also explored opportunities involving clinical trials and pharmaceutical distribution channels.

The company has controlled or operated assets associated with cannabis cultivation, extraction, and formulation technologies through its corporate structure and affiliated entities. ZYUS has also participated in collaborative arrangements with research institutions and healthcare-focused organizations to support product validation and therapeutic studies. Data regarding the scale of current international commercial operations and active joint ventures is limited in publicly available disclosures, and some operational details are inconclusive based on available public sources.

Strategic Position & Investments

ZYUS has strategically emphasized pharmaceutical-grade cannabinoid products and clinical validation rather than competing primarily in high-volume recreational cannabis markets. Its growth initiatives have included research partnerships, formulation development, intellectual property generation, and expansion into cannabinoid-based therapeutics targeting regulated healthcare markets. The company has also explored opportunities connected to bioscience innovation and precision cannabinoid delivery systems.

Historically, ZYUS has been associated with investments and acquisitions tied to cannabis cultivation infrastructure and downstream cannabinoid processing capabilities. The company’s strategic direction reflects broader industry trends toward medically oriented cannabinoid applications, including standardized dosing and evidence-backed treatment approaches. Public disclosures indicate continued interest in emerging cannabinoid science and healthcare applications, although some investment timelines and commercialization milestones remain uncertain based on currently available information.

Geographic Footprint

ZYUS Life Sciences Corporation is headquartered in Canada, with its operational base historically connected to the province of Saskatchewan. The company’s principal market presence has been concentrated within the Canadian medical cannabis and life sciences sectors, supported by domestic research, production, and regulatory activities. Canada remains the company’s primary operational and regulatory environment.

The company has also pursued broader market visibility through listings and investor access associated with North American capital markets, including over-the-counter trading in the United States. While ZYUS has expressed interest in broader international opportunities connected to cannabinoid therapeutics and pharmaceutical development, publicly verifiable information regarding significant operational footprints outside Canada remains limited.

Leadership & Governance

ZYUS leadership has historically emphasized scientific validation, pharmaceutical standards, and long-term healthcare market participation within the cannabinoid industry. The company’s governance structure reflects a combination of life sciences, agriculture, cannabis operations, and capital markets experience. Public filings and corporate disclosures indicate a strategic focus on transitioning from commodity cannabis exposure toward higher-value therapeutic and bioscience applications.

Key executives and leadership figures publicly associated with the company include:

• Brent Zettl – Chief Executive Officer
• Dennis Zettl – Executive leadership role associated with corporate operations and strategy
• Richard Findlay – Board and governance leadership involvement

Additional executive and governance information may vary across reporting periods and public disclosures. Certain leadership appointments and current officer roles are inconclusive based on available public sources.